Lyon Reaffirms 'Outperform' Rating for Hutchison China MediTech's Savolitinib Based on Positive Phase III Trial Data

2025-06-05 / Read about 0 minute

Author：小编

At the ASCO Annual Meeting, Hutchison China MediTech unveiled the latest findings from its Phase III clinical trial in China evaluating the combination therapy of savolitinib and osimertinib for the treatment of non-small cell lung cancer. The interim analysis revealed a significant efficacy, coupled with a favorable safety profile and a promising trend in overall survival, despite the data being preliminary. Lyon's research report underscores that these new data will bolster the expansion of savolitinib's indications in China, thereby reinforcing the 'Outperform' rating for Hutchison China MediTech with a target price of HK$30.7.

Previous page：UK Fintech Giant Wise Aims to Shift Primary Listin...

Next page：China Merchants Securities Initiates Coverage on T...

Return to List

Hot Reading

1 day ago

Elon Musk's Grok AI Spread Ludicrous Misinformation After Charlie Kirk's Shooting, Saying Kirk Survived and Video Was Fake

1 day ago

FTC launches inquiry into AI chatbot companions from Meta, OpenAI, and others

2 day ago

OpenAI Execs Are Extremely Upset

1 day ago

Financial Experts Concerned That Driving Users Into Psychosis Will Be Bad for AI Investments